Having trouble viewing this email? View in your browser.
 
Weekly News
13 July 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 
ECCMID 2021: our huge thanks!

From all of us at ESCMID, we would like to give our thanks to all members of our community that took part in the first ever fully-online ECCMID. All sessions will be available in the on-demand section of the ECCMID platform by the end of the week.

 
› Read more
 
ECCMID Certificates – Attendance and CME/CPD certification

Looking to get your CME/CPD certificate for ECCMID 2021? Be sure to visit the dedicated page on the ECCMID website which explains all of the details and which contains links to the congress evaluation.

It is necessary to complete the congress evaluation in order to receive the CME certificate.

19th ESCMID Summer School – last chance for attendance grant submissions!

Until 15 July, 2021, ESCMID members are able apply for an attendance grant, covering the registration fee (including accommodation) for the ESCMID Summer School in Carcavelos, Portugal (Travel is not included).

Find out more and apply on the Summer School Website.

ESCMID Executive Committee Elections 2021: Get your nominations in!

At the end of 2021, elections will be held among the membership to fill three (out of eight) positions in the ESCMID Executive Committee, one representing clinical microbiology and two infectious diseases.

ESCMID would like to encourage you to propose candidates by 31 August 2021 on the ESCMID website.

EMA communication: "Human Medicines Highlights" Newsletter - July 2021 issue

ESCMID is pleased to send you the latest edition of the monthly EMA Newsletter which includes decisions by EMA Scientific Committees and updates on medicines safety. We hope that you will find this useful.

You can access the Newsletter by clicking here. Previous editions can also be found on this page.

How to: prophylactic interventions for prevention of Clostridioides difficile infection

The authors reviewed here CDI prophylactic treatment strategies and their implementation in clinical practice. Based on the results retrieved, there are no proven effective, evidenced-based prophylaxis options for primary CDI. As for secondary prevention, FMT is considered the option of choice in patients with multiple recurrences.

Bezlotoxumab can be added to standard treatment for patients at high risk for R-CDI. The most promising strategies are those aimed at reducing changes in intestinal microbiota and development of a new effective non–toxin-based vaccine.